Compounding Pharmacies Reference

Why pharmacy traceability matters

Compounded tirzepatide reaches patients through one of two regulated pharmacy pathways under the U.S. Federal Food, Drug, and Cosmetic Act:

• Section 503A — Licensed compounding pharmacies. State-licensed; dispense patient-specific preparations under valid prescriptions; operate under USP <797> sterile compounding standards.
• Section 503B — FDA-registered outsourcing facilities. Federally registered; FDA-inspected; produce office-stock compounded medications under cGMP (current Good Manufacturing Practice).

Both are legally distinct from FDA-approved manufacturing. Compounded medications are not FDA-approved and are not the same as Mounjaro® or Zepbound® (Eli Lilly).

Provider-level Pillar 2 (Pharmacy traceability & CoA) of our v3.0 rubric evaluates whether telehealth providers publicly identify their pharmacy partners, support per-vial lot traceability, and supply USP <71> sterility, USP <85> bacterial endotoxin, and HPLC potency Certificates of Analysis on patient request. The pharmacies below are publicly identified as partners by providers in our directory.

Reviewed pharmacies

What patients should look for

• PCAB accreditation — voluntary third-party accreditation administered by ACHC; signals adherence to USP <797> sterile compounding standards above and beyond state minimums.
• 503A or 503B compliance — verifiable status. 503B facilities also appear in FDA's public Outsourcing Facility Registration database.
• Refrigerated overnight shipping for peptide injectables — preserves stability.
• Clear ingredient disclosure — tirzepatide base, not unrecognized salt forms (e.g., semaglutide sodium / acetate salts that have been targeted in FDA warning letters).
• Access to a licensed MD or DO — the prescriber relationship is what makes 503A patient-specific compounding lawful.
• Real titration guidance — not just refills. The clinical protocol should drive dose decisions.

Looking for tirzepatide? Our editorial #1 pick